No headlines found.
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
Globe Newswire (Wed, 1-May 8:01 AM ET)
Globe Newswire (Wed, 1-May 8:00 AM ET)
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
Globe Newswire (Mon, 15-Apr 8:00 AM ET)
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
Globe Newswire (Mon, 1-Apr 6:30 AM ET)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX
PRNewswire (Mon, 18-Mar 10:52 PM ET)
Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law Firm
PRNewswire (Fri, 15-Mar 12:54 PM ET)
INVESTIGATION UPDATE: Halper Sadeh LLC Investigates IGT, AKTX, SDPI, VIVK
Globe Newswire (Sat, 9-Mar 8:54 AM ET)
Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm
Globe Newswire (Fri, 8-Mar 4:38 PM ET)
Business Wire (Tue, 5-Mar 11:51 AM ET)
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.
As of May 10, 2024, AKTX stock price declined to $1.60 with 18,863 million shares trading.
AKTX has a beta of 0.65, meaning it tends to be less sensitive to market movements. AKTX has a correlation of 0.01 to the broad based SPY ETF.
AKTX has a market cap of $8.09 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AKTX stock traded as high as $39.80 and as low as $1.08.
AKTX has underperformed the market in the last year with a return of -54.5%, while the SPY ETF gained +27.8%. In the last 3 month period, AKTX fell short of the market, returning -33.3%, while SPY returned +4.2%. However, in the most recent 2 weeks AKTX has outperformed the stock market by returning +35.0%, while SPY returned +2.5%.
AKTX support price is $1.46 and resistance is $1.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX stock will trade within this expected range on the day.